TY - JOUR
T1 - New dextran coated activated carbons for medical use
AU - Howell, C. A.
AU - Sandeman, S. R.
AU - Zheng, Y.
AU - Mikhalovsky, S. V.
AU - Nikolaev, V. G.
AU - Sakhno, L. A.
AU - Snezhkova, E. A.
N1 - Funding Information:
This work was funded in part by the People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme ; International Research Staff Exchange Scheme programme , project MEAD-ET (Grant agreement no. 247547 FP7-PEOPLE-2009-IRSES ) and the Industry-Academia Partnerships and Pathways project ACROBAT (Grant agreement no. 286366 FP7-People-2011-IAPP ).
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Activated carbon (AC) can be used for blood purification (hemoperfusion) to treat a range of conditions by direct perfusion of blood through an adsorbent column. The clinical effects of hemoperfusion relate to the AC adsorptive capacity, and any inflammatory response generated by direct blood contact. The use of a biocompatible coating minimizes side-effects but at the same time significantly reduces AC adsorption capacity in particular towards substances with large molecular mass. We investigated the adsorption capacity for biological molecules in a wide range of molecular masses and biocompatibility of a dextran (Dx) coated mesoporous AC (HSGD) produced from a polymer precursor. The hemocompatibility of the Dx-coated beads was investigated according to the ISO guidelines. Coating the HSGD with a Dx coating (5-30% weight of AC) decreased the specific surface area and pore volume of the materials and reduced adsorption capacity for methylene blue, vitamin B12, bilirubin and albumin, while minimizing fines production. Even the partially coated materials did not activate the inflammatory response and thus could be considered hemocompatible, with the Dx coating reducing fibrinogen adsorption and complement generation, suggesting the material warrants continued development for hemoperfusion applications.
AB - Activated carbon (AC) can be used for blood purification (hemoperfusion) to treat a range of conditions by direct perfusion of blood through an adsorbent column. The clinical effects of hemoperfusion relate to the AC adsorptive capacity, and any inflammatory response generated by direct blood contact. The use of a biocompatible coating minimizes side-effects but at the same time significantly reduces AC adsorption capacity in particular towards substances with large molecular mass. We investigated the adsorption capacity for biological molecules in a wide range of molecular masses and biocompatibility of a dextran (Dx) coated mesoporous AC (HSGD) produced from a polymer precursor. The hemocompatibility of the Dx-coated beads was investigated according to the ISO guidelines. Coating the HSGD with a Dx coating (5-30% weight of AC) decreased the specific surface area and pore volume of the materials and reduced adsorption capacity for methylene blue, vitamin B12, bilirubin and albumin, while minimizing fines production. Even the partially coated materials did not activate the inflammatory response and thus could be considered hemocompatible, with the Dx coating reducing fibrinogen adsorption and complement generation, suggesting the material warrants continued development for hemoperfusion applications.
UR - http://www.scopus.com/inward/record.url?scp=84945354775&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945354775&partnerID=8YFLogxK
U2 - 10.1016/j.carbon.2015.09.042
DO - 10.1016/j.carbon.2015.09.042
M3 - Article
AN - SCOPUS:84945354775
VL - 97
SP - 134
EP - 146
JO - Carbon
JF - Carbon
SN - 0008-6223
ER -